Canadian pharmaceutical and biotechnology company Innocan Pharma Corporation (CSE:INNO) (FSE:IP40) (OTCQB:INNPD) announced on Monday the publication of a research article titled 'Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial' in the peer reviewed journal Frontiers in Veterinary Science.

Findings include a significant improvement in behavior/function reported by owners (p = 0.0217), with 100% of dogs showing improved function after LPT-CBD vs 25% after placebo, and significant reduction in lameness (Visual Lameness Scale; p = 0.033) and pain (interactive VAS; p = 0.005) following LPT-CBD administration in comparison to placebo LPT-CBD injection provided a sustained-release profile, with measurable plasma CBD concentrations lasting up to four weeks. All dogs in the trial tolerated LPT-CBD, with only minor, self-resolving adverse events (a short-lived fever and a transient injection-site swelling that was resolved within a few days without treatment).

This study demonstrates that a single subcutaneous injection of LPT-CBD produced sustained improvements in long-term pain-related outcomes and overall wellbeing in client-owned dogs with naturally occurring osteoarthritis for up to four weeks, with a statistically significant superiority over placebo, Innocan said.

Dr. Eyal Kalo, vice president of Research and Development, said: "We are encouraged by these results, particularly given LPT-CBD's potential as a long-acting approach to pain management in both veterinary and human settings. We have initiated ongoing discussions with FDA, including the Center for Veterinary Medicine (CVM) and the human analgesic and anesthetic department of the FDA, to support the advancement of LPT-CBD across both markets."